Journal of Clinical Nutrition and Metabolism

Short Communication A SCITECHNOL JOURNAL

Obesity and Type 2 Diabetes: Pathophysiology and Therapeutic Interventions

Steven Jonathan*

Department of Gastroenterology, Centre for Nutrition and Bowel Disease, Aalborg University Hospital, Aalborg, Denmark

***Corresponding Author:** Steven Jonathan, Department of Gastroenterology, Centre for Nutrition and Bowel Disease, Aalborg University Hospital, Aalborg, Denmark; E-mail: jonathans@aalborg.dk

Received date: 22 May, 2023, Manuscript No. JCNM-23-106835;

Editor assigned date: 24 May, 2023, Pre QC. JCNM-23-106835(PQ);

Reviewed date: 07 June, 2023, QC No. JCNM-23-106835;

Revised date: 15 June, 2023, Manuscript No. JCNM-23-106835(R);

Published date: 22 June, 2023, DOI: 10.35841/jcnm.1000123

Description

Obesity and type 2 diabetes have reached epidemic proportions worldwide, posing significant health and economic burdens. The strong association between obesity and type 2 diabetes has been extensively studied, with obesity considered a major risk factor for the development of insulin resistance and subsequent type 2 diabetes. This brief study aims to provide an overview of the pathophysiological mechanisms linking obesity to type 2 diabetes and explore therapeutic interventions targeting these pathways [1].

Pathophysiology of obesity and insulin resistance

Obesity-induced insulin resistance plays a pivotal role in the development of type 2 diabetes. Excessive adipose tissue, especially visceral fat, leads to chronic low-grade inflammation and dysregulation of adipokines, resulting in systemic insulin resistance. Adipose tissue-derived pro-inflammatory cytokines, such as Tumor Necrosis Factor-Alpha (TNF-α) and Inter Leukin-6 (IL-6), impair insulin signaling pathways in peripheral tissues like skeletal muscle, liver, and adipose tissue. Additionally, adipose tissue dysfunction disrupts adiponectin secretion, an adipokine with insulin-sensitizing effects. Increased circulating free fatty acids further contribute to insulin resistance by interfering with insulin signaling [2].

Role of adipose tissue in diabetes pathogenesis

Adipose tissue acts as an endocrine organ, secreting various adipokines that modulate insulin sensitivity and glucose homeostasis. In obesity, adipose tissue dysfunction leads to altered adipokine production. Adiponectin, with its anti-inflammatory and insulin-sensitizing properties, is decreased, while leptin, resistin, and visfatin, which promote insulin resistance, are elevated. These imbalances contribute to a pro-inflammatory and insulin-resistant state. Adipose tissue macrophage infiltration further amplifies inflammation and insulin resistance [3-6].

Gut microbiota and metabolic dysfunction

Emerging evidence suggests that the gut microbiota plays an important role in obesity-related metabolic dysfunction. Obese individuals have altered gut microbial composition characterized by a reduced diversity and an increased abundance of pro-inflammatory bacterial species. Dysbiosis can trigger metabolic endotoxemia, where Lipopolysaccharides (LPS) derived from the gut bacteria enter the circulation, activating Toll-Like Receptor 4 (TLR4) and promoting systemic inflammation and insulin resistance. Modulating the gut microbiota through probiotics, prebiotics, or fecal microbiota transplantation shows potential as a therapeutic approach for improving metabolic health [7,8].

Therapeutic interventions for obesity and type 2 diabetes

Lifestyle modifications, including dietary changes and increased physical activity, form the cornerstone of obesity and type 2 diabetes management. Calorie restriction, adopting a balanced diet rich in fiber, whole grains, fruits, vegetables, and lean proteins, and regular exercise can lead to weight loss, improved insulin sensitivity, and glycemic control [9,10]. Pharmacological interventions, such as metformin, thiazolidinediones, GLP-1 receptor agonists, and SGLT2 inhibitors, target various aspects of the pathophysiology, including insulin resistance, glucose regulation, and weight reduction. Bariatric surgery, particularly Roux-en-Y gastric bypass and sleeve gastrectomy, induces substantial weight loss and metabolic improvements in severely obese individuals with type 2 diabetes [11].

Conclusion

Obesity and type 2 diabetes share complex pathophysiological mechanisms, with obesity acting as a significant risk factor for the development of insulin resistance and subsequent type 2 diabetes. Understanding the intricate interplay between adipose tissue dysfunction, inflammation, gut microbiota, and insulin resistance provides insights into potential therapeutic targets. Lifestyle modifications, pharmacological interventions, and bariatric surgery represent valuable strategies for managing obesity and improving glycemic control in individuals with type 2 diabetes. Further research is needed to explore novel therapeutic approaches and optimize personalized interventions to combat the growing burden of obesity and type 2 diabetes.

References

1. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M (2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376:595-605.
2. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S (2011) Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obes 19:110-120.
3. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H (2013) A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obes 21:935-943.
4. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H (2013) Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 36:4022-4029.

5. Makowski CT, Gwinn KM, Hurren KM (2011) Naltrexone/bupropion: An investigational combination for weight loss and maintenance. Obes Facts 4:489-494.
6. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB (2016) Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: A randomized clinical trial. J Am Med Assoc 315:990-1004.
7. Verpeut JL, Bello NT (2014) Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opin Drug Saf 13:831-841.
8. Caterson ID (1999) Obesity and its management. Exp Clin Pharmacol 22:12-16.
9. Greenway FL, Dunayevich E, Tollefson G, Erickson J (2009) Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 94:4898-4906.
10. Caprio M, Infante M, Moriconi E, Armani A, Fabbri A (2019) Very-Low-Calorie Ketogenic Diet (VLCKD) in the management of metabolic diseases: Systematic review and consensus statement from the Italian Society of Endocrinology (SIE). J Endocrinol Invest 42:1365-1386.
11. Jebb SA, Aveyard PN, Hawkes C (2013) The evolution of policy and actions to tackle obesity in England. Obes Rev 14:42-59.